TY - JOUR
T1 - Challenges in Re-Irradiation in the Thorax
T2 - Managing Patients with Locally Recurrent Non-Small Cell Lung Cancer
AU - Fischer-Valuck, Benjamin W.
AU - Robinson, Clifford G.
AU - Simone, Charles B.
AU - Gomez, Daniel R.
AU - Bradley, Jeffrey D.
N1 - Funding Information:
CGR: Leadership: Radialogica; Stock and Other Ownership Interests: Radialogica; Consulting or Advisory Role: Varian Medical Systems, AstraZeneca, EMD Serono; Research Funding: Varian Medical Systems (Inst), Elekta (Inst), Merck (Inst); Patents, Royalties, Other Intellectual Property: Noninvasive imaging and treatment system for cardiac arrhythmias WO 2017078757 A1, US Provisional Application No. 62/598,162 entitled System and Method for Determining Segments for Ablation; Travel, Accommodations, Expenses: Siemens Healthineers.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/7
Y1 - 2020/7
N2 - Treatment of locally recurrent non-small lung cancer (NSCLC) after definitive chemoradiation therapy is challenging as patients are often inoperable and systemic therapy alone frequently results in suboptimal outcomes. Re-irradiation of NSCLC may be the best strategy for treating locoregional failures with the goal of durable long-term control and potentially cure. Repeat irradiation is technically challenging for fear of life-threatening toxicities to previously irradiated organs at risk while also delivering definitive doses of radiation to recurrent disease. No standard guidelines exist with regards to re-irradiation technique and re-treatment dose constraints to organs at risks. We herein describe a case of locoregional recurrence after definitive chemoradiation therapy for NSCLC with expert opinions for subsequent management. As described and guided by our experts, we review the various techniques for repeat radiation therapy, treatment planning goals, and reported toxicities and outcomes in the re-irradiation setting.
AB - Treatment of locally recurrent non-small lung cancer (NSCLC) after definitive chemoradiation therapy is challenging as patients are often inoperable and systemic therapy alone frequently results in suboptimal outcomes. Re-irradiation of NSCLC may be the best strategy for treating locoregional failures with the goal of durable long-term control and potentially cure. Repeat irradiation is technically challenging for fear of life-threatening toxicities to previously irradiated organs at risk while also delivering definitive doses of radiation to recurrent disease. No standard guidelines exist with regards to re-irradiation technique and re-treatment dose constraints to organs at risks. We herein describe a case of locoregional recurrence after definitive chemoradiation therapy for NSCLC with expert opinions for subsequent management. As described and guided by our experts, we review the various techniques for repeat radiation therapy, treatment planning goals, and reported toxicities and outcomes in the re-irradiation setting.
UR - http://www.scopus.com/inward/record.url?scp=85081908800&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2020.02.001
DO - 10.1016/j.semradonc.2020.02.001
M3 - Review article
C2 - 32503787
AN - SCOPUS:85081908800
SN - 1053-4296
VL - 30
SP - 223
EP - 231
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 3
ER -